Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 5/2012

Open Access 01-10-2012 | Original Paper

The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country

Authors: Mehlika Toy, Fatih Oguz Onder, Ramazan Idilman, Gokhan Kabacam, Jan Hendrik Richardus, Mithat Bozdayi, Meral Akdogan, Zarife Kuloglu, Aydan Kansu, Solko Schalm, Cihan Yurdaydin

Published in: The European Journal of Health Economics | Issue 5/2012

Login to get access

Abstract

Background/aims

Chronic hepatitis B (CHB) infection is a serious public health problem due to its potential liver disease sequelae and highly expensive medical costs such as the need for liver transplantation. The aim of this study was to quantify the burden of active CHB in terms of mortality and morbidity, the eligibility of antiviral treatment and to assess various treatment scenarios and possible salvage combinations for cost-effectiveness.

Methods

A population cohort from a large data base of chronic hepatitis B patients was constructed and stratified according to 10-year age groups, the prevalence of HBsAg, HBV DNA level, ALT level, HBeAg status and the presence of cirrhosis. An age-specific Markov model for disease progression and cost-effectiveness analysis was constructed and calibrated for the specific population setting.

Results

Of about 3.2 million estimated HBsAg carriers, 25 % are eligible for treatment. If the active cohort remains untreated, 31 % will die due to liver related complications. Within a 20-year period, 11 % will have developed decompensated cirrhosis, 12 % liver cancer and 6 % will need liver transplantation. Quality adjusted life years (QALYs) for the no treatment scenario ranged from 9.3 to 14.0. For scenarios with antiviral treatment, QALYs ranged from 9.9 to 14.5 for lamivudine, 13.0–17.5 for salvage therapy, and 16.6–19.0 for the third generation drugs entecavir and tenofovir.

Conclusion

In a country with considerable amount of active CHB patients, monotherapy with a highly potent third generation drug has the most health-gain, and is cost-effective in both HBeAg-positive and negative in all stages of liver disease.
Appendix
Available only for authorised users
Literature
1.
Lavanchy, D.: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 11(2), 97–107 (2004)PubMedCrossRef
2.
European Association For The Study of The Liver: EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 50(2), 227–242 (2009)CrossRef
3.
4.
Ferenci, P., Fried, M., Labrecque, D., Bruix, J., Sherman, M., Omata, M., Heathcote, J., Piratsivuth, T., Kew, M., Otegbayo, J.A., Zheng, S.S., Sarin, S., Hamid, S.S., Modawi, S.B., Fleig, W., Fedail, S., Thomson, A., Khan, A., Malfertheiner, P., Lau, G., Carillo, F.J., Krabshuis, J., Le Mair, A.: World Gastroenterology O: Hepatocellular carcinoma (HCC): a global perspective. J. Clin. Gastroenterol. 44(4), 239–245 (2010). doi:10.​1097/​MCG.​0b013e3181d46ef2​ PubMedCrossRef
5.
Yurdaydin, C., Akarca, U.: Treatment of chronic hepatitis B with telbuvidine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited. Liver Int. 31(5), 589–591 (2011)
6.
Toy, M., Onder, F.O., Wormann, T., Bozdayi, M., Schalm, S.W., Borsboom, G.J., Idilman, R., Richardus, J.H., Yurdaydin, C.: Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BioMed Central Infect. Dis. 11, 337 (2011)
7.
8.
Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S.G., Goodman, Z., Wulfsohn, M.S., Xiong, S., Fry, J., Brosgart, C.L.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348(9), 800–807 (2003)PubMedCrossRef
9.
Janssen, H.L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U.S., Cakaloglu, Y., Simon, C., So, T.M., Gerken, G., de Man, R.A., Niesters, H.G., Zondervan, P., Hansen, B., Schalm, S.W.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365(9454), 123–129 (2005)PubMedCrossRef
10.
Kanwal, F., Gralnek, I.M., Martin, P., Dulai, G.S., Farid, M., Spiegel, B.M.: Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann. Intern. Med. 142(10), 821–831 (2005)PubMed
11.
Fattovich, G., Bortolotti, F., Donato, F.: Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 48, 335–352 (2008)PubMedCrossRef
12.
Fattovich, G., Pantalena, M., Zagni, I., Realdi, G., Schalm, S.W., Christensen, E.: Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am. J. Gastroenterol. 97(11), 2886–2895 (2002)PubMedCrossRef
13.
Fattovich, G., Giustina, G., Schalm, S.W., Hadziyannis, S., Sanchez-Tapias, J., Almasio, P., Christensen, E., Krogsgaard, K., Degos, F., Carneiro de Moura, M., et al.: Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 21(1), 77–82 (1995)PubMed
14.
Realdi, G., Fattovich, G., Hadziyannis, S., Schalm, S.W., Almasio, P., Sanchez-Tapias, J., Christensen, E., Giustina, G., Noventa, F.: Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J. Hepatol. 21(4), 656–666 (1994)PubMedCrossRef
15.
Kanwal, F., Farid, M., Martin, P., Chen, G., Gralnek, I.M., Dulai, G.S., Spiegel, B.M.: Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am. J. Gastroenterol. 101(9), 2076–2089 (2006)PubMedCrossRef
16.
Chang, T.T., Gish, R.G., de Man, R., Gadano, A., Sollano, J., Chao, Y.C., Lok, A.S., Han, K.H., Goodman, Z., Zhu, J., Cross, A., DeHertogh, D., Wilber, R., Colonno, R., Apelian, D.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354(10), 1001–1010 (2006)PubMedCrossRef
17.
Lai, C.L., Shouval, D., Lok, A.S., Chang, T.T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R.C., Cross, A., Colonno, R., Fernandes, L.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354(10), 1011–1020 (2006)PubMedCrossRef
18.
Colonno, R.J., Rose, R.E., Pokornowski, K., Baldick, C.J., Eggers, B., Xu, D., Cross, A., Tenney, D.J.: Four year assessment of entecavir resistance in nucleoside naïve and lamivudine refractory patients. J. Hepatol. 46(Suppl. 1), S294 (2007)CrossRef
19.
Lai, C.L., Dienstag, J., Schiff, E., Leung, N.W., Atkins, M., Hunt, C., Brown, N., Woessner, M., Boehme, R., Condreay, L.: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36(6), 687–696 (2003)PubMedCrossRef
20.
Moskovitz, D.N., Osiowy, C., Giles, E., Tomlinson, G., Heathcote, E.J.: Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J. Viral Hepat. 12(4), 398–404 (2005)PubMedCrossRef
21.
Lee, Y.S., Suh, D.J., Lim, Y.S., Jung, S.W., Kim, K.M., Lee, H.C., Chung, Y.H., Lee, Y.S., Yoo, W., Kim, S.O.: Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43(6), 1385–1391 (2006)PubMedCrossRef
22.
Chen, C.H., Wang, J.H., Lee, C.M., Hung, C.H., Hu, T.H., Wang, J.C., Lu, S.N., Changchien, C.S.: Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir. Ther. 11(6), 771–778 (2006)PubMed
23.
Yeon, J.E., Yoo, W., Hong, S.P., Chang, Y.J., Yu, S.K., Kim, J.H., Seo, Y.S., Chung, H.J., Moon, M.S., Kim, S.O., Byun, K.S., Lee, C.H.: Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 55(10), 1488–1495 (2006)PubMedCrossRef
24.
Liaw, Y.F., Sung, J.J., Chow, W.C., Farrell, G., Lee, C.Z., Yuen, H., Tanwandee, T., Tao, Q.M., Shue, K., Keene, O.N., Dixon, J.S., Gray, D.F., Sabbat, J.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351(15), 1521–1531 (2004)PubMedCrossRef
25.
Colonno, R.J., Rose, R., Baldick, C.J., Levine, S., Pokornowski, K., Yu, C.F., Walsh, A., Fang, J., Hsu, M., Mazzucco, C., Eggers, B., Zhang, S., Plym, M., Klesczewski, K., Tenney, D.J.: Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44(6), 1656–1665 (2006)PubMedCrossRef
26.
Tenney, D.J., Rose, R.E., Baldick, C.J., Pokornowski, K.A., Eggers, B.J., Fang, J., Wichroski, M.J., Xu, D., Yang, J., Wilber, R.B., Colonno, R.J.: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49(5), 1503–1514 (2009)PubMedCrossRef
27.
Heathcote, E.J., Marcellin, P., Buti, M., Gane, E., De Man, R.A., Krastev, Z., Germanidis, G., Lee, S.S., Flisiak, R., Kaita, K., Manns, M., Kotzev, I., Tchernev, K., Buggisch, P., Weilert, F., Kurdas, O.O., Shiffman, M.L., Trinh, H., Gurel, S., Snow-Lampart, A., Borroto-Esoda, K., Mondou, E., Anderson, J., Sorbel, J., Rousseau, F.: Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140(1), 132–143 (2011). doi:10.​1053/​j.​gastro.​2010.​10.​011 PubMedCrossRef
28.
van Bommel, F., Wunsche, T., Mauss, S., Reinke, P., Bergk, A., Schurmann, D., Wiedenmann, B., Berg, T.: Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40(6), 1421–1425 (2004)PubMedCrossRef
29.
Sarin, N., Yim, C., Feld, J.J., Heathcote, E.J., Wong, D.K.: Tenofovir is effective salvage therapy for nucleoside-resistant hepatitis B. abstract nr: 454, AASLD 2009 Boston (2009)
30.
Van Bommel, F., De Man, R., Ferenci, P., Reijnders, J.G., Bronowicki, J.P., Fulop, B., Wedemeyer, H., Erhardt, A., Hueppe, D., Bourliere, M., Sarrazin, C., Trojan, J., Buggisch, P., Petersen, J., Spenger, U., Brost, S., Pariente, A., Schuchmann, M., Wasmuth, H.E., Deterding, K., Rutter, K., Feucht, H.H., Wiedenmann, B., Berg, T.: Long-term follow-up evaluation of the efficacy and safety of tenofovir disoproxil fumarate (TDF) in a european multicenter (nucleos(t)ide experienced) hepatitis B virus HBV infected cohort. abstract nr: 221, AASLD 2009 Boston (2009)
31.
Reijnders, J.G., Janssen, H.L.: Potency of tenofovir in chronic hepatitis B: mono or combination therapy? J. Hepatol. 48(3), 383–386 (2008)PubMedCrossRef
32.
Lau, G.K., Piratvisuth, T., Luo, K.X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M.W., Chow, W.C., Paik, S.W., Chang, W.Y., Berg, T., Flisiak, R., McCloud, P., Pluck, N.: Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352(26), 2682–2695 (2005)PubMedCrossRef
33.
Marcellin, P., Bonino, F., Lau, G.K., Farci, P., Yurdaydin, C., Piratvisuth, T., Jin, R., Gurel, S., Lu, Z.M., Wu, J., Popescu, M., Hadziyannis, S.: Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 136(7), 2169–2179 e2161–2164 (2009)
34.
Cooksley, W.G., Piratvisuth, T., Lee, S.D., Mahachai, V., Chao, Y.C., Tanwandee, T., Chutaputti, A., Chang, W.Y., Zahm, F.E., Pluck, N.: Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepat. 10(4), 298–305 (2003)PubMedCrossRef
35.
Piratvisuth, T., Lau, G., Chao, Y.C., Jin, R., Chutaputti, A., Zhang, Q.B., Tanwandee, T., Button, P., Popescu, M.: Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol. Int. 2(1), 102–110 (2008)PubMedCrossRef
36.
Fleurence, R.L., Hollenbeak, C.S.: Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics 25(1), 3–6 (2007)PubMedCrossRef
37.
Kennedy, P.T., Phillips, N., Chandrasekhar, J., Jacobs, R., Jacobs, M., Dusheiko, G.: Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping. Liver Int. 28(5), 699–704 (2008)PubMedCrossRef
38.
Shouval, D., Lai, C.L., Chang, T.T., Cheinquer, H., Martin, P., Carosi, G., Han, S., Kaymakoglu, S., Tamez, R., Yang, J., Tenney, D., Brett-Smith, H.: Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J. Hepatol. 50(2), 289–295 (2009)PubMedCrossRef
39.
Reijnders, J.G., Perquin, M.J., Zhang, N., Hansen, B.E., Janssen, H.L.: Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 139(2), 491–498 (2010)PubMedCrossRef
40.
Marcellin, P., Lau, G.K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., Lu, Z.M., Piratvisuth, T., Germanidis, G., Yurdaydin, C., Diago, M., Gurel, S., Lai, M.Y., Button, P., Pluck, N.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351(12), 1206–1217 (2004)PubMedCrossRef
41.
Keeffe, E.B., Zeuzem, S., Koff, R.S., Dieterich, D.T., Esteban-Mur, R., Gane, E.J., Jacobson, I.M., Lim, S.G., Naoumov, N., Marcellin, P., Piratvisuth, T., Zoulim, F.: Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 5(8), 890–897 (2007). doi:10.​1016/​j.​cgh.​2007.​05.​004 PubMedCrossRef
42.
Chang, T.T.: On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatol. Int. 3(Suppl 1), 16–23 (2009)PubMedCrossRef
43.
Lai, C.L., Gane, E., Liaw, Y.F., Hsu, C.W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E.J., Rasenack, J., Bzowej, N., Naoumov, N.V., Di Bisceglie, A.M., Zeuzem, S., Moon, Y.M., Goodman, Z., Chao, G., Constance, B.F., Brown, N.A.: Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357(25), 2576–2588 (2007)PubMedCrossRef
44.
Hadziyannis, A.S., Mitsoula, P.V., Hadziyannis, S.J.: Prediction of long-term maintenance of virologic response during lamivudine treatment in HBeAg-negative chronic hepatitis B. Hepatology 46(Suppl. 1), 667A (2007)
45.
46.
Levy, A.R., Kowdley, K.V., Iloeje, U., Tafesse, E., Mukherjee, J., Gish, R., Bzowej, N., Briggs, A.H.: The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 11(3), 527–538 (2008)PubMedCrossRef
47.
Gold, M.R., Siegel, J.E., Russel, L.B., Weinstein, M.G.: Cost-Effectiveness in Health and Medicine. Oxford University Press, New York (1996)
48.
Drummond, M.F., Jefferson, T.O.: Guidelines for authors and peer reviewers of economic submissions to the BMJ the BMJ economic evaluation working party. BMJ 313(7052), 275–283 (1996)PubMedCrossRef
49.
50.
Karasu, Z., Akyildiz, M., Kilic, M., Zeytunlu, M., Aydin, U., Tekin, F., Yilmaz, F., Ozacar, T., Akarca, U., Ersoz, G., Gunsar, F., Ilter, T., Lucey, M.R.: Living donor liver transplantation for hepatitis B cirrhosis. J. Gastroenterol. Hepatol. 22(12), 2124–2129 (2007). doi:10.​1111/​j.​1440-1746.​2006.​04782.​x PubMedCrossRef
51.
Woo, G., Tomlinson, G., Nishikawa, Y., Kowgier, M., Sherman, M., Wong, D.K., Pham, B., Ungar, W.J., Einarson, T.R., Heathcote, E.J., Krahn, M.: Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and bayesian meta-analyses. Gastroenterology 139(4), 1218–1229 e1215 (2010). doi:10.​1053/​j.​gastro.​2010.​06.​042
52.
Akarca, U.S.: Chronic hepatitis B. A guideline to diagnosis, approach, management, and follow-up 2007. Turkish Association for the Study of Liver. Turk. J. Gastroenterol. 19(4), 207–230 (2008)PubMed
53.
Toy, M., Veldhuijzen, I.K., de Man, R.A., Richardus, J.H., Schalm, S.W.: Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology 50(3), 743–751 (2009)PubMedCrossRef
54.
Wong, J.B., Koff, R.S., Tine, F., Pauker, S.G.: Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann. Intern. Med. 122(9), 664–675 (1995)PubMed
55.
Spackman, D.E., Veenstra, D.L.: A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 26(11), 937–949 (2008)PubMedCrossRef
56.
Shepherd, J., Jones, J., Takeda, A., Davidson, P., Price, A.: Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol. Assess. 10(28), iii–iv, xi–xiv, 1–183 (2006)
57.
58.
Barbieri, M., Drummond, M., Willke, R., Chancellor, J., Jolain, B., Towse, A.: Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 8(1), 10–23 (2005)PubMedCrossRef
Metadata
Title
The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country
Authors
Mehlika Toy
Fatih Oguz Onder
Ramazan Idilman
Gokhan Kabacam
Jan Hendrik Richardus
Mithat Bozdayi
Meral Akdogan
Zarife Kuloglu
Aydan Kansu
Solko Schalm
Cihan Yurdaydin
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 5/2012
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-012-0413-8

Other articles of this Issue 5/2012

The European Journal of Health Economics 5/2012 Go to the issue

Original Paper

Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale

Original Paper

Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab

Original Paper

Assessing preferences for improved smoking cessation medications: a discrete choice experiment

Original Paper

Disease progression and costs of care in Alzheimer’s disease patients treated with donepezil: a longitudinal naturalistic cohort

Original Paper

Cost-effectiveness of open versus laparoscopic appendectomy: a multilevel approach with propensity score matching

Original Paper

Genetic testing in the European Union: does economic evaluation matter?